<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40927274</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2752-4191</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>European heart journal open</Title><ISOAbbreviation>Eur Heart J Open</ISOAbbreviation></Journal><ArticleTitle>Morning administration of anthracyclines is associated with a lower risk of cancer therapy-related cardiac dysfunction.</ArticleTitle><Pagination><StartPage>oeaf100</StartPage><MedlinePgn>oeaf100</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">oeaf100</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ehjopen/oeaf100</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="UNASSIGNED">Pre-clinical studies point towards an administration time-dependency of anthracycline-induced cancer therapy-related cardiac dysfunction (CTRCD). This retrospective study aimed to investigate the association between time-of-day of AC administration and CTRCD.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="UNASSIGNED">Patients from two cardio-oncology outpatient clinics, treated with ACs for any malignancy, were included. Percentage of afternoon AC administration was calculated: cumulative dose administered in the afternoon (12 p.m.-11:59 p.m.)/total cumulative dose. Three groups were defined: morning group &#x2265; 50% of ACs in the morning (12 a.m.-11:59 a.m.), afternoon group &#x2265; 50% of ACs in the afternoon, and intermediate group = exactly 50% of ACs in the morning and afternoon. Associations between AC timing and occurrence of CTRCD and heart failure (HF) were assessed using survival analyses. Of 270 included patients, 66 developed CTRCD and 17 developed HF. Compared with the morning group, the afternoon group had a higher risk of developing CTRCD: hazard ratio (HR) 2.88 (95% CI: 1.52-5.44). When considering percentage of ACs administered in the afternoon as a continuous variable, the HR for developing CTRCD was 1.14 (95% CI: 1.04-1.24) for each subsequent 10% of afternoon administration. Results were consistent across sensitivity analyses of age, sex, body mass index, malignancy type, cumulative AC dose, and HFA-ICOS risk score. Congruently, the continuous variable of afternoon AC administration was associated with higher risk of HF: HR = 1.19 (95% CI: 1.01-1.41).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Afternoon administration of ACs is associated with an increased risk of developing CTRCD and HF, suggesting that morning administration may be preferred. Before widespread implementation, these findings should be confirmed in an RCT.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Printezi</LastName><ForeName>Markella I</ForeName><Initials>MI</Initials><Identifier Source="ORCID">0000-0001-6265-6230</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teske</LastName><ForeName>Arco J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0001-5305-1619</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuithoff</LastName><ForeName>Nicolaas P A</ForeName><Initials>NPA</Initials><Identifier Source="ORCID">0000-0002-4441-1448</Identifier><AffiliationInfo><Affiliation>Department of Data Science and Biostatistics, Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, Universiteitsweg 100, 3584 CX Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urgel</LastName><ForeName>Kim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, St. Antonius Hospital Nieuwegein, Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bijlsma</LastName><ForeName>Rhod&#xe9; M</ForeName><Initials>RM</Initials><Identifier Source="ORCID">0000-0003-0980-6652</Identifier><AffiliationInfo><Affiliation>Department of Medical Oncology, Cancer Centre, University Medical Centre Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Rhenen</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2276-8806</Identifier><AffiliationInfo><Affiliation>Department of Haematology, University Medical Centre Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cramer</LastName><ForeName>Maarten Jan</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Punt</LastName><ForeName>Cornelis J A</ForeName><Initials>CJA</Initials><Identifier Source="ORCID">0000-0003-0846-1445</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Universiteitsweg 100, 3584 CX Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>May</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Universiteitsweg 100, 3584 CX Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Laake</LastName><ForeName>Linda W</ForeName><Initials>LW</Initials><Identifier Source="ORCID">0000-0002-5027-0661</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J Open</MedlineTA><NlmUniqueID>9918282081406676</NlmUniqueID><ISSNLinking>2752-4191</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anthracycline</Keyword><Keyword MajorTopicYN="N">Cardiotoxicity</Keyword><Keyword MajorTopicYN="N">Chronotherapy</Keyword><Keyword MajorTopicYN="N">Circadian</Keyword><Keyword MajorTopicYN="N">Doxorubicin</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword></KeywordList><CoiStatement>Conflict of interest: All authors declare to have no competing interests. N.P.A.Z. is a collaborator on projects financed by Ely Lilly, Sanofi, Pfizer and LEO Pharma, this does not constitute a conflict of interest in relation to the work presented in this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>10</Day><Hour>4</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40927274</ArticleId><ArticleId IdType="pmc">PMC12415182</ArticleId><ArticleId IdType="doi">10.1093/ehjopen/oeaf100</ArticleId><ArticleId IdType="pii">oeaf100</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lyon &#xa0;AR, L&#xf3;pez-Fern&#xe1;ndez &#xa0;T, Couch &#xa0;LS, Asteggiano &#xa0;R, Aznar &#xa0;MC, Bergler-Klein &#xa0;J, Boriani &#xa0;G, Cardinale &#xa0;D, Cordoba &#xa0;R, Cosyns &#xa0;B, Cutter &#xa0;DJ, de Azambuja &#xa0;E, de Boer &#xa0;RA, Dent &#xa0;SF, Farmakis &#xa0;D, Gevaert &#xa0;SA, Gorog &#xa0;DA, Herrmann &#xa0;J, Lenihan &#xa0;D, Moslehi &#xa0;J, Moura &#xa0;B, Salinger &#xa0;SS, Stephens &#xa0;R, Suter &#xa0;TM, Szmit &#xa0;S, Tamargo &#xa0;J, Thavendiranathan &#xa0;P, Tocchetti &#xa0;CG, van der Meer &#xa0;P, van der Pal &#xa0;HJH; ESC Scientific Document Group . 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J &#xa0;2022;43:4229&#x2013;4361.</Citation><ArticleIdList><ArticleId IdType="pubmed">36017568</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal &#xa0;J, Francis &#xa0;L, Reid &#xa0;J, Murray &#xa0;S, Denvir &#xa0;M. Quality of life in patients with chronic heart failure and their carers: a 3-year follow-up study assessing hospitalization and mortality. Eur J Heart Fail &#xa0;2010;12:1002&#x2013;1008.</Citation><ArticleIdList><ArticleId IdType="pubmed">20615920</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinale &#xa0;D, Colombo &#xa0;A, Bacchiani &#xa0;G, Tedeschi &#xa0;I, Meroni &#xa0;CA, Veglia &#xa0;F, Civelli &#xa0;M, Lamantia &#xa0;G, Colombo &#xa0;N, Curigliano &#xa0;G, Fiorentini &#xa0;C, Cipolla &#xa0;CM. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation &#xa0;2015;131:1981&#x2013;1988.</Citation><ArticleIdList><ArticleId IdType="pubmed">25948538</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotrionte &#xa0;M, Biondi-Zoccai &#xa0;G, Abbate &#xa0;A, Lanzetta &#xa0;G, D'Ascenzo &#xa0;F, Malavasi &#xa0;V, Peruzzi &#xa0;M, Frati &#xa0;G, Palazzoni &#xa0;G. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol &#xa0;2013;112:1980&#x2013;1984.</Citation><ArticleIdList><ArticleId IdType="pubmed">24075281</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivero-Santana &#xa0;B, Salda&#xf1;a-Garc&#xed;a &#xa0;J, Caro-Cod&#xf3;n &#xa0;J, Zamora &#xa0;P, Moliner &#xa0;P, Mart&#xed;nez Monzonis &#xa0;A, Zatarain &#xa0;E, &#xc1;lvarez-Ortega &#xa0;C, G&#xf3;mez-Prieto &#xa0;P, Pernas &#xa0;S, Rodriguez &#xa0;I, Bu&#xf1;o Soto &#xa0;A, Cadenas &#xa0;R, Palacios Ozores &#xa0;P, P&#xe9;rez Ram&#xed;rez &#xa0;S, Merino Salvador &#xa0;M, Valbuena &#xa0;S, Fern&#xe1;ndez Gasso &#xa0;L, Ju&#xe1;rez &#xa0;V, Severo &#xa0;A, Terol &#xa0;B, de Soto &#xc1;lvarez &#xa0;T, Rodr&#xed;guez &#xa0;O, Brion &#xa0;M, Gonz&#xe1;lez-Costello &#xa0;J, Canales Albendea &#xa0;M, Gonz&#xe1;lez-Juanatey &#xa0;JR, Moreno &#xa0;R, L&#xf3;pez-Send&#xf3;n &#xa0;J, L&#xf3;pez-Fern&#xe1;ndez &#xa0;T. Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. Eur Heart J &#xa0;2025;46:273&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">39106857</ArticleId></ArticleIdList></Reference><Reference><Citation>
Ferlay J, Laversanne M, Ervik M, Lam F, Colombet M, Mery L, Pi&#xf1;eros M, Znaor A, Soerjomataram I, Bray F . Global Cancer Observatory: Cancer Tomorrow (version 1.1). Lyon, France: International Agency for Research on Cancer; 2024. https://gco.iarc.who.int/tomorrow. Date accessed 29 August 2024.</Citation></Reference><Reference><Citation>Printezi &#xa0;MI, Kilgallen &#xa0;AB, Bond &#xa0;MJG, &#x160;tibler &#xa0;U, Putker &#xa0;M, Teske &#xa0;AJ, Cramer &#xa0;MJ, Punt &#xa0;CJA, Sluijter &#xa0;JPG, Huitema &#xa0;ADR, May &#xa0;AM, van Laake &#xa0;LW. Toxicity and efficacy of chronomodulated chemotherapy: a systematic review. Lancet Oncol &#xa0;2022;23:e129&#x2013;e143.</Citation><ArticleIdList><ArticleId IdType="pubmed">35240088</ArticleId></ArticleIdList></Reference><Reference><Citation>Dierickx &#xa0;P, Vermunt &#xa0;MW, Muraro &#xa0;MJ, Creyghton &#xa0;MP, Doevendans &#xa0;PA, van Oudenaarden &#xa0;A, Geijsen &#xa0;N, Van Laake &#xa0;LW. Circadian networks in human embryonic stem cell-derived cardiomyocytes. EMBO Rep &#xa0;2017;18:1199&#x2013;1212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494509</ArticleId><ArticleId IdType="pubmed">28536247</ArticleId></ArticleIdList></Reference><Reference><Citation>du Pr&#xe9; &#xa0;BC, Dierickx &#xa0;P, Crnko &#xa0;S, Doevendans &#xa0;PA, Vos &#xa0;MA, Geijsen &#xa0;N, Neutel &#xa0;D, van Veen &#xa0;TAB, van Laake &#xa0;LW. Neonatal rat cardiomyocytes as an in vitro model for circadian rhythms in the heart. J Mol Cell Cardiol &#xa0;2017;112:58&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">28823816</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang &#xa0;N, Ma &#xa0;H, Jiang &#xa0;Z, Niu &#xa0;L, Zhang &#xa0;X, Liu &#xa0;Y, Wang &#xa0;Y, Cheng &#xa0;S, Deng &#xa0;Y, Qi &#xa0;H, Wang &#xa0;Z. Dosing depending on SIRT3 activity attenuates doxorubicin-induced cardiotoxicity via elevated tolerance against mitochondrial dysfunction and oxidative stress. Biochem Biophys Res Commun &#xa0;2019;517:111&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">31303273</ArticleId></ArticleIdList></Reference><Reference><Citation>Sancar &#xa0;A, Van Gelder &#xa0;RN. Clocks, cancer, and chronochemotherapy. Science &#xa0;2021;371:eabb0738.</Citation><ArticleIdList><ArticleId IdType="pubmed">33384351</ArticleId></ArticleIdList></Reference><Reference><Citation>Waggoner &#xa0;SN. Circadian rhythms in immunity. Curr Allergy Asthma Rep &#xa0;2020;20:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7357859</ArticleId><ArticleId IdType="pubmed">31925560</ArticleId></ArticleIdList></Reference><Reference><Citation>Okyar &#xa0;A, Ozturk Civelek &#xa0;D, Akyel &#xa0;YK, Surme &#xa0;S, Pala Kara &#xa0;Z, Kavakli &#xa0;IH. The role of the circadian timing system on drug metabolism and detoxification: an update. Expert Opin Drug Metab Toxicol &#xa0;2024;20:503&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">38753451</ArticleId></ArticleIdList></Reference><Reference><Citation>Crnko &#xa0;S, Du Pr&#xe9; &#xa0;BC, Sluijter &#xa0;JPG, Van Laake &#xa0;LW. Circadian rhythms and the molecular clock in cardiovascular biology and disease. Nat Rev Cardiol &#xa0;2019;16:437&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">30796369</ArticleId></ArticleIdList></Reference><Reference><Citation>Avagimyan &#xa0;A, Pogosova &#xa0;N, Kakturskiy &#xa0;L, Sheibani &#xa0;M, Challa &#xa0;A, Kogan &#xa0;E, Fogacci &#xa0;F, Mikhaleva &#xa0;L, Vandysheva &#xa0;R, Yakubovskaya &#xa0;M, Faggiano &#xa0;A, Carugo &#xa0;S, Urazova &#xa0;O, Jahanbin &#xa0;B, Lesovaya &#xa0;E, Polana &#xa0;S, Kirsanov &#xa0;K, Sattar &#xa0;Y, Trofimenko &#xa0;A, Demura &#xa0;T, Saghazadeh &#xa0;A, Koliakos &#xa0;G, Shafie &#xa0;D, Alizadehasl &#xa0;A, Cicero &#xa0;A, Costabel &#xa0;JP, Biondi-Zoccai &#xa0;G, Ottaviani &#xa0;G, Sarrafzadegan &#xa0;N. Doxorubicin-related cardiotoxicity: review of fundamental pathways of cardiovascular system injury. Cardiovasc Pathol &#xa0;2024;73:107683.</Citation><ArticleIdList><ArticleId IdType="pubmed">39111556</ArticleId></ArticleIdList></Reference><Reference><Citation>European Parliament and Council . Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). OJ &#xa0;2016;L119:1&#x2013;88.</Citation></Reference><Reference><Citation>Kamphuis &#xa0;JAM, Linschoten &#xa0;M, Cramer &#xa0;MJ, Alsemgeest &#xa0;F, van Kessel &#xa0;DJW, Urgel &#xa0;K, Post &#xa0;MC, Manintveld &#xa0;OC, Hassing &#xa0;HC, Liesting &#xa0;C, Wardeh &#xa0;AJ, Olde Bijvank &#xa0;EGM, Schaap &#xa0;J, Stevense-den Boer &#xa0;AM, Doevendans &#xa0;PA, Asselbergs &#xa0;FW, Teske &#xa0;AJ. ONCOR: design of the Dutch cardio-oncology registry. Neth Heart J &#xa0;2021;29:288&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8062648</ArticleId><ArticleId IdType="pubmed">33201485</ArticleId></ArticleIdList></Reference><Reference><Citation>Teske &#xa0;AJ, Linschoten &#xa0;M, Kamphuis &#xa0;JAM, Naaktgeboren &#xa0;WR, Leiner &#xa0;T, van der Wall &#xa0;E, Kuball &#xa0;J, van Rhenen &#xa0;A, Doevendans &#xa0;PA, Cramer &#xa0;MJ, Asselbergs &#xa0;FW. Cardio-oncology: an overview on outpatient management and future developments. Neth Heart J &#xa0;2018;26:521&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6220023</ArticleId><ArticleId IdType="pubmed">30141030</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann &#xa0;J, Lerman &#xa0;A, Sandhu &#xa0;NP, Villarraga &#xa0;HR, Mulvagh &#xa0;SL, Kohli &#xa0;M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc &#xa0;2014;89:1287&#x2013;1306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4258909</ArticleId><ArticleId IdType="pubmed">25192616</ArticleId></ArticleIdList></Reference><Reference><Citation>Plana &#xa0;JC, Galderisi &#xa0;M, Barac &#xa0;A, Ewer &#xa0;MS, Ky &#xa0;B, Scherrer-Crosbie &#xa0;M, Ganame &#xa0;J, Sebag &#xa0;IA, Agler &#xa0;DA, Badano &#xa0;LP, Banchs &#xa0;J, Cardinale &#xa0;D, Carver &#xa0;J, Cerqueira &#xa0;M, DeCara &#xa0;JM, Edvardsen &#xa0;T, Flamm &#xa0;SD, Force &#xa0;T, Griffin &#xa0;BP, Jerusalem &#xa0;G, Liu &#xa0;JE, Magalh&#xe3;es &#xa0;A, Marwick &#xa0;T, Sanchez &#xa0;LY, Sicari &#xa0;R, Villarraga &#xa0;HR, Lancellotti &#xa0;P. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr &#xa0;2014;27:911&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">25172399</ArticleId></ArticleIdList></Reference><Reference><Citation>Feijen &#xa0;EAM, Leisenring &#xa0;WM, Stratton &#xa0;KL, Ness &#xa0;KK, van der Pal &#xa0;HJH, van Dalen &#xa0;EC, Armstrong &#xa0;GT, Aune &#xa0;GJ, Green &#xa0;DM, Hudson &#xa0;MM, Loonen &#xa0;J, Oeffinger &#xa0;KC, Robison &#xa0;LL, Yasui &#xa0;Y, Kremer &#xa0;LCM, Chow &#xa0;EJ. Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity. JAMA Oncol &#xa0;2019;5:864&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6490232</ArticleId><ArticleId IdType="pubmed">30703192</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dalen &#xa0;EC, van der Pal &#xa0;HJH, Kremer &#xa0;LCM. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Cochrane Database Syst Rev &#xa0;2016;3:CD005008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6457744</ArticleId><ArticleId IdType="pubmed">26938118</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu &#xa0;Y, Gehr &#xa0;AW, Anikpo &#xa0;I, Meadows &#xa0;RJ, Craten &#xa0;KJ, Narra &#xa0;K, Lingam &#xa0;A, Kamath &#xa0;S, Tanna &#xa0;B, Ghabach &#xa0;B, Ojha &#xa0;RP. Cardiotoxicity among socioeconomically marginalized breast cancer patients. Breast Cancer Res Treat &#xa0;2022;195:401&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9464741</ArticleId><ArticleId IdType="pubmed">35971056</ArticleId></ArticleIdList></Reference><Reference><Citation>
Statistics Netherlands . Sociaal-economische status per postcode, 2020 en 2021&#x2014;incl. studenten. https://www.cbs.nl/. Date accessed 16 February 2024.</Citation></Reference><Reference><Citation>Lyon &#xa0;AR, Dent &#xa0;S, Stanway &#xa0;S, Earl &#xa0;H, Brezden-Masley &#xa0;C, Cohen-Solal &#xa0;A, Tocchetti &#xa0;CG, Moslehi &#xa0;JJ, Groarke &#xa0;JD, Bergler-Klein &#xa0;J, Khoo &#xa0;V, Tan &#xa0;LL, Anker &#xa0;MS, von Haehling &#xa0;S, Maack &#xa0;C, Pudil &#xa0;R, Barac &#xa0;A, Thavendiranathan &#xa0;P, Ky &#xa0;B, Neilan &#xa0;TG, Belenkov &#xa0;Y, Rosen &#xa0;SD, Iakobishvili &#xa0;Z, Sverdlov &#xa0;AL, Hajjar &#xa0;LA, Macedo &#xa0;AVS, Manisty &#xa0;C, Ciardiello &#xa0;F, Farmakis &#xa0;D, de Boer &#xa0;RA, Skouri &#xa0;H, Suter &#xa0;TM, Cardinale &#xa0;D, Witteles &#xa0;RM, Fradley &#xa0;MG, Herrmann &#xa0;J, Cornell &#xa0;RF, Wechelaker &#xa0;A, Mauro &#xa0;MJ, Milojkovic &#xa0;D, de Lavallade &#xa0;H, Ruschitzka &#xa0;F, Coats &#xa0;AJS, Seferovic &#xa0;PM, Chioncel &#xa0;O, Thum &#xa0;T, Bauersachs &#xa0;J, Andres &#xa0;MS, Wright &#xa0;DJ, L&#xf3;pez-Fern&#xe1;ndez &#xa0;T, Plummer &#xa0;C, Lenihan &#xa0;D. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail &#xa0;2020;22:1945&#x2013;1960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8019326</ArticleId><ArticleId IdType="pubmed">32463967</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallion &#xa0;HH, Brunetto &#xa0;VL, Cibull &#xa0;M, Lentz &#xa0;SS, Reid &#xa0;G, Soper &#xa0;JT, Burger &#xa0;RA, Andersen &#xa0;W; Gynecologic Oncology Group Study . Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol &#xa0;2003;21:3808&#x2013;3813.</Citation><ArticleIdList><ArticleId IdType="pubmed">14551299</ArticleId></ArticleIdList></Reference><Reference><Citation>Hrushesky &#xa0;W, Wood &#xa0;P, Levi &#xa0;F, von Roemeling &#xa0;R, Bjarnason &#xa0;G, Focan &#xa0;C, Meier &#xa0;K, Corn&#xe9;lissen &#xa0;G, Halberg &#xa0;F. A recent illustration of some essentials of circadian chronotherapy study design. J Clin Oncol &#xa0;2004;22:2971&#x2013;2972.</Citation><ArticleIdList><ArticleId IdType="pubmed">15254067</ArticleId></ArticleIdList></Reference><Reference><Citation>Canal &#xa0;P, Sqall &#xa0;A, de Forni &#xa0;M, Chevreau &#xa0;C, Pujol &#xa0;A, Bugat &#xa0;R, Roche &#xa0;H, Oustrin &#xa0;J, Houin &#xa0;G. Chronopharmacokinetics of doxorubicin in patients with breast cancer. Eur J Clin Pharmacol &#xa0;1991;40:287&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">2060566</ArticleId></ArticleIdList></Reference><Reference><Citation>
Netherlands Cancer Registry (NCR) . Netherlands Comprehensive Cancer Organisation (IKNL). https://iknl.nl/en/ncr. Date accessed 26 August 2024.</Citation></Reference><Reference><Citation>Kim &#xa0;DW, Byun &#xa0;JM, Lee &#xa0;JO, Kim &#xa0;JK, Koh &#xa0;Y. Chemotherapy delivery time affects treatment outcomes of female patients with diffuse large B cell lymphoma. JCI Insight &#xa0;2023;8;e164767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9977288</ArticleId><ArticleId IdType="pubmed">36512421</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacchetti &#xa0;S, Dugu&#xe9; &#xa0;PA, Innominato &#xa0;PF, Bjarnason &#xa0;GA, Focan &#xa0;C, Garufi &#xa0;C, Tumolo &#xa0;S, Coudert &#xa0;B, Iacobelli &#xa0;S, Smaaland &#xa0;R, Tampellini &#xa0;M, Adam &#xa0;R, Moreau &#xa0;T, L&#xe9;vi &#xa0;F; ARTBC International Chronotherapy Group . Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis. Ann Oncol &#xa0;2012;23:3110&#x2013;3116.</Citation><ArticleIdList><ArticleId IdType="pubmed">22745214</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>